Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 841

A longstanding problem in optics holds that an improved resolution in imaging is offset by a loss in the depth of focus. Now, scientists are joining computation with X-ray imaging as they develop a new and exciting technique to bypass this limitation.

The upcoming Advanced Photon Source Upgrade (APS-U) project at Argonne will put this problem under one of the brightest spotlights imaginable. The upgrade will make the APS, a Department of Energy Office of Science User Facility, 500 times brighter than it is today, further enhancing the capabilities of its X-rays to study the arrangements of atoms and molecules in a wide range of biological and technological materials.

“A whole variety of X-ray imaging experiments ultimately will need something like this as they all push the resolution to finer length scales in the future,” said Chris Jacobsen, an Argonne Distinguished Fellow and professor of physics at Northwestern University. With the Upgrade in place, the APS’s X-rays could allow scientists to study systems like the brain’s full network of synaptic connections, or the entire volume of an integrated circuit down to its finest details.

Read more

Mild cognitive impairment (MCI) is an intermediate stage between the expected cognitive decline of normal aging and the more-serious decline of dementia. It can involve problems with memory, language, thinking, and judgment that are greater than normal age-related changes.

If you have mild cognitive impairment, you may be aware that your memory or mental function has “slipped.” Your family and close friends also may notice a change. But generally these changes aren’t severe enough to significantly interfere with your day-to-day life and usual activities.

Mild cognitive impairment may increase your risk of later progressing to dementia, caused by Alzheimer’s disease or other neurological conditions. But some people with mild cognitive impairment never get worse, and a few eventually get better.

Read more

The past few years have brought lots of good news for anyone who considers coffee a vice. Scientists have discovered that various compounds in coffee can help fight a number of diseases including Alzheimer’s, and now a new study is putting even more weight behind the notion that coffee is very good for you.

The work, which was published in Proceedings of the National Academy of Sciences, suggests that not only does coffee battle Parkinson’s but also another incurable brain disease called Lewy body dementia. Conducted by scientists at Rutgers, the study points to the combined effects of caffeine and a fatty acid present in coffee called EHT as potentially playing key roles in disease fighting.

Read more

Having separate neuronal correlates for appetitive and aversive behavior in our brain may explain why we are striving for ever-greater rewards while simultaneously minimizing threats and dangers. Such balanced behavior of approach-and-avoidance learning is surely helpful for surviving competition in a constantly changing environment.

Dopamine has a reputation as the key player in the brain’s reward circuits, making us seek out pleasurable experiences, but growing evidence points to a multipronged role for the neurotransmitter. In particular, dopamine may also reinforce avoidance of painful experiences. UC Berkeley researchers have now mapped dopamine neurons in the brain with fiber photometry and discovered two parallel dopamine circuits driving attractive and aversive reinforcement learning and motivation.

Read more

D esigner therapies are treatments tailored to a specific disease, and nowhere is the need greater for new therapies than in a group of nervous system disorders, known as “neurodegenerative diseases.”

Many of these diseases are common and well-known, such as Alzheimer’s or Parkinson’s disease. However, some are very rare, genetic disorders that are the consequence of a defective gene. In all these diseases, a mutant protein that misfolds causes the degeneration and death of neurons. One effective therapeutic strategy is to prevent the rogue protein from ever being made.

Spinocerebellar ataxia type 7 (SCA7) is one such disease in which nerves in different parts of the brain, including the eye, degenerate, which leads to blindness and difficulty walking, speaking, and balancing. SCA7 is dominantly inherited — which means that you just need one bad copy of the mutation to cause disease. The disease occurs when a short section of DNA that encodes ataxin-7 gene is erroneously repeated — like a word in a book printed two or three times. In this case, three chemical units of the DNA sequence — C-A-G — are repeated over and over.

Read more

New research suggests that exposure to childhood adversity is associated with reduced cognitive control and alterations in key brain networks. The findings, which appear in the journal Social Cognitive and Affective Neuroscience, could help explain the link between childhood adversity and depression.

“My work focuses on how we can use objective biomarkers to aid in clinical decision making,” said study author Scott A. Langenecker of the University of Utah.

“One challenging clinical decision point is what to do when individuals have recovered from a depressive episode. Do we continue treatment? Do we exercise regular check-ins? Or do we just wait and see?”

Read more

Newborns with vitamin D deficiency have an increased risk of schizophrenia later in life, a team of Australian and Danish researchers has reported.

The discovery could help prevent some cases of the disease by treating vitamin D deficiency during the earliest stages of life.

The study, led by Professor John McGrath from The University of Queensland (UQ) in Australia and Aarhus University in Denmark, found newborns with vitamin D deficiency had a 44 per cent increased risk of being diagnosed with schizophrenia as adults compared to those with normal vitamin D levels.

Read more